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Does testosterone mediate the relationship
between vitamin D and prostate cancer? A
systematic review and meta-analysis
protocol
Luke A. Robles1,2 , Karen Dawe1,2, Richard M. Martin1,2,3, Julian P. T. Higgins1,2 and Sarah J. Lewis1,2*
Abstract
Background: Evidence from studies on prostate cancer progression have identified vitamin D to be a potentially
important nutrient. However, the World Cancer Research Fund and American Institute for Cancer Research have
reported the quality of this evidence to be limited and warrant further investigation. We plan to use the recently
developed WCRF International/University of Bristol mechanistic systematic review framework to determine whether
the observed association between vitamin D and prostate cancer exists through a plausible biological pathway.
Methods: This protocol sets out how we will perform a systematic review of the literature in human and animal
studies. We will search the electronic databases MEDLINE, EMBASE, PubMed, and BIOSIS Citation Index without
restrictions on year of publication or language. We will extract data from observational and experimental studies
examining two inter-linked pathways in the relationship between vitamin D and prostate cancer progression: (1)
vitamin D and testosterone, and (2) testosterone and prostate cancer progression. We focus on testosterone as its
actions form a potentially novel intermediate mechanism that was identified via our online literature mining tools.
The outcomes of interest include incidence or prevalence of prostate cancer, measures of prostate cancer progression
(including biochemical recurrence, local, or distal metastases), and prostate cancer-specific mortality. We will assess
study quality and the level of certainty of the evidence. We will analyse data where possible, using meta-analysis with
forest plots or albatross plots; otherwise, a narrative synthesis will be performed.
Discussion: To our knowledge, this will be the first systematic synthesis of the evidence underpinning the vitamin
D-testosterone-prostate cancer mechanistic pathway. The results of the review may inform future research, intervention
trials, and public health messages.
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Background
Prostate cancer is the second most commonly diagnosed
cancer and the fifth leading cause of cancer death in
men worldwide [1]. The causes of prostate cancer are
not well understood, but well-established risk factors are
older age [2], Afro-Caribbean or West African origin [3],
and having a first-degree relative (father, brother)
diagnosed with the disease [4]. None of these factors are
modifiable or controllable through intervention. Other
putative risk factors for prostate cancer include obesity,
physical activity, and diet. These lifestyle factors are
amenable with intervention but definitive evidence that
they are causally associated with prostate cancer is
lacking.
The World Cancer Research Fund Continuous Update
Project [5] reviewed the literature on certain nutrients
associated with prostate cancer including vitamin D, and
found the evidence was limited and inconclusive regard-
ing their effects on prostate cancer. However, the
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vitamin D receptor is active in many tissues, including
prostate tissue [6], and ecologic studies suggest that in
regions where sun exposure (the major source of vita-
min D) is high there is a reduced risk of prostate cancer
[7, 8]. Individual-level observational studies report in-
consistent results, with both high and low vitamin D
concentrations associated with an increased risk of pros-
tate cancer [9, 10]. These inconsistencies may be ex-
plained by small sample sizes or confounders of the
vitamin D-prostate cancer relationship. With regards to
prostate cancer progression (rather than incidence),
there is randomised controlled trial evidence suggesting
a modest effect of interventions to increase vitamin D
using supplements on measures of disease progression
(PSA levels, decrease in number of positive cores, and
Gleason score), among men with low and intermediate
stage prostate cancer [11, 12].
Vitamin D is a precursor to the steroid hormone calci-
triol, which regulates calcium and phosphate and has an
important role in bone mineralisation [13]. The majority
of vitamin D is obtained from exposure to sunlight
which is synthesised through the skin in the form of
cholecalciferol (vitamin D3). A smaller proportion of
vitamin D comes from diet as ergocalciferol (vitamin
D2). Vitamin D is converted into calcitriol through two
hydroxylation steps: first, cholecalciferol is hydroxylated
in the liver into 25-hydroxy vitamin D; second, circulat-
ing 25-hydroxy vitamin D is hydroxylated in the kidney
to produce calcitriol (1,25(OH)2D) [13].
Vitamin D increases differentiation and apoptosis, and
decreases proliferation and metastasis in prostate cancer
cells [14]. However, identifying which mechanism ex-
plains the association between vitamin D and prostate
cancer, and systematically reviewing the evidence for this
mechanism is complex. We, therefore, plan to use a re-
cently developed two-stage methodology (the WCRF
International/University of Bristol methodology) to syn-
thesise the evidence from mechanistic studies [15]. We
have already carried out step 1 of this process, in which
we have used two web-based text mining tools to gener-
ate our mechanistic hypothesis. TeMMPo (Text Mining
for Mechanism Prioritisation) [16] uses MeSH descrip-
tors to quantify the literature on predefined intermediate
concept terms between an exposure and an outcome
through co-occurrence (i.e. two concepts that occur fre-
quently together in the same article). TeMMPo provides
a priority score to assist with identifying novel inter-
mediate concept terms that have a substantial literature
resource. MELODI (Mining Enriched Literature Objects
to Derive Intermediates) [17] uses MeSH and free text
terms to identify overlapping concept terms between
two custom article sets. We first used MELODI to yield
novel intermediate concept terms, which were then en-
tered into TeMMPo to assist with prioritising terms.
Two co-authors reviewed the first 20 highest ranked
intermediate terms produced by TeMMPo and agreed on
a potential mechanism using a process of elimination.
Seven of the highest ranked terms were eliminated; four
terms were too broad (i.e. ribonucleic acid (RNA), RNA
messenger, CD4 (gene), nicotinamide adenine dinucleo-
tide), and three terms related to endogenous retroviruses,
which have no well-known drug targets nor are amenable
with behavioural intervention. The highest ranked term
was a gene (i.e. HSD3B1) involved in androgen metabol-
ism followed by testosterone (ranked ninth) after eliminat-
ing the other seven terms. Testosterone was, therefore,
chosen as the mechanism for investigation.
Testosterone is a male sex hormone that is produced
by the testis and adrenal glands, with a critical role in
driving cell division in the prostate. Testosterone binds
to proteins (sex hormone-binding globulin and albumin)
in the blood whilst a small proportion of it is unbound
(free testosterone); total testosterone concentrations
refer to the combination of bound and free testosterone.
Normal total testosterone levels in healthy men are
between 300 and 1050 ng/dl. The androgen hypothesis [18]
suggests prostate cancer onset or progression is driven by
androgens, which is supported by animal models [19] and
the observation that castration or high-dose oestrogen
therapy to reduce serum testosterone subsequently reduces
metastatic prostate cancer. Therapeutic or surgical (castra-
tion) androgen deprivation is used clinically to reduce tes-
tosterone production in the treatment of prostate cancer.
The relationship between vitamin D and testosterone is
not well-understood, although there is randomised pla-
cebo controlled trial [20] and observational [21, 22] evi-
dence of a positive relationship between vitamin D and
both total and free testosterone, suggesting testosterone is
a plausible biological intermediate on the mechanistic
pathway between vitamin D and prostate cancer progres-
sion. A review of mechanistic studies is, therefore, war-
ranted to support the existence of this relationship.
Our systematic review aims to synthesise the evidence
from human and animal studies to investigate whether
testosterone is a causal intermediate in the mechanistic
pathway between vitamin D and prostate cancer.
As the potential importance of this relationship is only
just emerging, few studies are likely to assess both vita-
min D and testosterone in relation to prostate cancer.
Therefore, relevant indirect evidence will be drawn from
studies of the two pathways: (1) studies linking vitamin
D to testosterone; and (2) studies linking testosterone to
prostate cancer.
Methods
Standards of reporting
This protocol was written in accordance with the Preferred
Reporting Items for Systematic review and Meta-Analysis
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Protocols (PRISMA-P) 2015 statement [23]. A populated
checklist for this review protocol has been provided in
Additional file 1.
Inclusion and exclusion criteria
Studies must meet the following criteria for the two
pathways addressed in the review.
Vitamin D-testosterone criteria
 Participants: human or animal—with measures of
vitamin D as the exposure and testosterone (free or
total testosterone) as the outcome;
 Exposures: any duration, frequency, and dose of
vitamin D, including nutrition supplements, and
sunlight exposure;
 Outcome: serum or plasma levels of total and/or
free testosterone.
Testosterone-prostate cancer criteria
 Participants: human or animal—with measures of
testosterone (free or total testosterone) as the
exposure and prostate cancer as the outcome;
 Exposure: any duration, frequency, and dose of
testosterone, including therapeutic use for non-
cancerous conditions;
 Outcomes: incidence or prevalence of prostate
cancer, number and size of tumour, measures of
prostate cancer progression (including biochemical
recurrence, local or distal metastases) and prostate
cancer-specific mortality;
 Observational studies (cohort, case-control) and ex-
perimental studies (randomised controlled trials,
cross-over studies) will be eligible for the review.
The following studies will be excluded:
 Studies investigating treatment effects of
testosterone on prostate cancer (e.g.
androgen deprivation therapy);
 Cell culture and animal studies presenting cell line
data only;
 Observational studies where the exposure is
measured within 2 years of the outcome to reduce
the risk of reverse causality.
Peer-reviewed published articles, including supplements
and meeting abstracts, are eligible sources of information
about the studies. Systematic and non-systematic reviews,
books, commentaries, and letters will be used to identify
studies not identified within the database searches. There
will be no restriction on language or publication date of
articles.
Search strategy
The following databases will be used to identify relevant
published articles without year or language restrictions:
 PubMed (from inception to present)
 Ovid MEDLINE (from 1946 to present)
 Ovid EMBASE (from 1980 to present)
 BIOSIS Citation Index (1969 to present)
Two sets of searches will be performed: (1) studies
that link the exposure of interest (vitamin D) to the
intermediate phenotype (testosterone), and (2) studies
that link the same intermediate phenotype to prostate
cancer onset or progression. Search strategies will in-
clude standard controlled vocabulary (MeSH and
Emtree), text words, and keywords. An example of the
search strategy used in MEDLINE is shown in Add-
itional file 2. The search strategy will be amended to ac-
commodate the individual requirements of each
database. An information specialist with experience of
conducting systematic reviews will be consulted regard-
ing the search strategy.
Searching other resources
Relevant systematic reviews will be used to identify eli-
gible studies not retrieved from the electronic searches.
The reference lists of all included articles will be hand
searched for additional studies. Subject experts will be
contacted about any unpublished or published studies
that were not yielded from the original search.
Data management
References yielded from the literature searches will be
imported first into Endnote for initial inspection. Du-
plicate references will be identified by importing each
reference into Stata and analysing the title, author
names, year of publication, and journal name for
overlap. We will use EPPI-Reviewer [24] and other
tools to assist with screening the references
Selection of studies
Titles and abstracts of all articles yielded from the lit-
erature searches will be screened against the eligibility
criteria. This process will be performed independently
by two reviewers, who will base their decision for
inclusion or exclusion on the criteria listed above.
Where an abstract is not available, the full-text article
will be reviewed. Any discrepancies found in the ini-
tial screening will be resolved through discussion with
a third reviewer. The full text of potential articles for
inclusion will also be screened independently with
any discrepancies resolved through discussion. The
reference list of all included articles will be searched
for additional studies.
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Data extraction
The following data items will be extracted independently
by two reviewers from the included studies using a pre-
defined extraction tool:
 Publication information—article title, author details,
publication type, year of study, location;
 Study population—sample size, demographics
(age, ethnicity), cancer stage, comorbidities
associated with testosterone levels (i.e.
hypogonadism);
 Exposure or intervention—study or model design,
intervention description (including type, dose and
duration), length of follow-up;
 Outcomes—measures of serum or plasma level of
total and/or free testosterone, and measures of
prostate cancer progression (tumour stage, Gleason
score, local and distant metastases, biochemical
recurrence based on prostate-specific antigen [PSA]
levels);
 Statistical measures—effect estimates (mean,
standard deviation, p value, odds ratio, 95%
confidence intervals); any model adjustments.
The extraction tool will be piloted by the two re-
viewers on a small sample of articles before the full ex-
traction process is undertaken. Any disagreements found
in all the data extractions will be resolved through dis-
cussion with a third reviewer.
Quality assessment
Assessments of risk of bias in individual studies will be
performed. Appropriate tools are available for different
study designs involving humans [25–27]. To assess risk
of bias in animal studies, the Systematic Review Centre
for Laboratory animal Experimentation (SYRCLE) tool
[28] will be used. Assessments will be performed inde-
pendently by two reviewers with discrepancies resolved
through discussion with a third reviewer. A summary
table presenting risk of bias assessments for each study
will be included in the review.
Data synthesis and analysis
Data will be synthesised in accordance with the separate
pathways (i.e. vitamin D-testosterone and testosterone-
prostate cancer). Human and animal trials will be ana-
lysed separately. It is anticipated that there will be a
large degree of heterogeneity between the studies, such
as differences in study design (e.g. RCT, case-control),
exposures (vitamin D, sunlight), measures, and samples.
Meta-analyses will be performed only with studies that
are sufficiently similar, using both random-effects and
fixed-effect methods. Primary results will be from
fixed-effects meta-analyses unless we observe strong
evidence of heterogeneity in effect sizes and study sizes.
The extent of statistical heterogeneity among the true
effects across studies will be assessed using the
between-study variance. If the studies cannot be judged
to be answering comparable research questions, for ex-
ample, if they differ substantially in methods, exposures,
or outcomes, a narrative synthesis will be performed.
Where possible, sub-group analysis will be performed to
examine the sources of heterogeneity on study out-
comes. Fixed-effect results will be presented graphically
using forest plots. Alternatively, albatross plots [29] will
be produced where effect sizes are not comparable.
Level of certainty of evidence
The level of certainty of evidence provided from all stud-
ies will be assessed using the Grading of Recommenda-
tions Assessment, Development and Evaluation system
(GRADE) [30]. GRADE classifies the confidence in an
estimate into four levels: (1) high, (2) moderate, (3) low,
and (4) very low. Estimates of effect can be either up or
downgraded based on several of the following criteria:
 Study limitations (risk of bias);
 Inconsistency of results;
 Indirectness of evidence;
 Imprecision;
 Reporting bias.
A study rated as low certainty could be upgraded if
the studies have reported a large magnitude of effect or
a dose-response relationship, for example. Human and
animal studies will be rated separately.
Discussion
The aim of this review is to determine whether testoster-
one is a causally relevant intermediate mechanism
underpinning the relationship between vitamin D and
prostate cancer progression.
To our knowledge, this is the first review examining
this mechanistic pathway in accordance with systematic-
ally synthesising the evidence of the relationship be-
tween vitamin D and testosterone. Other reviews have
investigated the relationship between testosterone and
prostate cancer outcomes, including increased risk in
prostate cancer in hypogonadal men. However, many of
these reviews tended to focus on the therapeutic use of
testosterone to assess treatment efficacy for cancer [31,
32]. Here, we will review evidence from studies involving
humans and experimental studies with rodents accord-
ing to the WCRF International/University of Bristol
methodology [15]. The synthesis of this evidence will
suggest whether increase in vitamin D is a potential pre-
ventive measure of prostate cancer progression.
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The search strategy and study inclusion criteria are
relatively broad to capture the wealth of evidence which
may exist. For human studies, no restrictions will be
placed on population characteristics (i.e. co-morbidities,
age), except where applicable (i.e. testosterone-prostate
cancer relationship). Different modes of administration
of the exposure variables (vitamin D, testosterone) and
multiple outcomes of prostate cancer will be considered
for inclusion in this review.
The review will exclude in vitro studies. These studies
are beneficial to the understanding of the mechanistic
pathway in terms of cellular and molecular activity.
However, it is difficult for in vitro studies to mimic the
complicated process that would occur within a natural
biological context. They would also increase the hetero-
geneity of the synthesised results due to the number of
different models that exist in these studies [33]. There-
fore, human and in vivo animal studies will be consid-
ered for inclusion as their data will have more clinical
relevance.
This review seeks to establish whether vitamin D is a
potential therapeutic intervention for the prevention
and/or progression of prostate cancer via its effects on
testosterone levels. Based on its findings, the review may
help inform future clinical intervention trials and other
types of research, such as public health messages.
Additional files
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